Efficacy of Adalimumab as Therapy for Hidradenitis Suppurativa: a Systematic Review
Abstract
Background: Adalimumab (ADA) is a monoclonal antibody that is widely used as a biologic therapy for immune diseases, one of which is hidradenitis suppurativa (HS). To date, evidence-based therapeutic approaches have not been commonly used for standard of care and this is likely due to the lack of related research and the diverse therapeutic options. ADA biologic therapy shows satisfactory results and is approved by the FDA for moderate to severe HS in adult patients. Aim: Provide an overview of the current evidence regarding the treatment of HS with ADA. Methods: A literature search related to Hidradenitis Suppurativa Clinical Response (HiSCR) was performed on the PubMed, Scopus, and EbscoHost databases with an ADA focus on HS treatment to achieve HiSCR. Full text analysis of 8 RCT studies that met the inclusion and exclusion criteria and used a critically reviewed questionnaire from the CEBM University of Oxford. Result: In this systematic review we obtained 8 RCTs for evaluation. The results showed that the prevalence of HiSCR after exposure to high doses of ADA, this statement was supported by 4 studies of RR>1, meaning that the addition of ADA gave patients more opportunities to achieve HiSCR. Another finding was a decrease in Sartorius scores and DLQI after ADA treatment. ADA can reduce depressive symptoms and increase pain, this statement is supported by two studies using the PHQ and PGA-SP scores. Conclusion: ADA has good efficacy against HS, as evidenced by the high prevalence of HiSCR and quality of life of patients.
Keywords
References
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology. 2015 Aug 20;231(2):184–90.
Lipsker D, Severac F, Freysz M, Sauleau E, Boer J, Emtestam L, et al. The ABC of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions. Dermatology. 2016 Apr 1;232(2):137–42.
Naldi L. Epidemiology. In: Hidradenitis Suppurativa [Internet]. Springer, Berlin, Heidelberg ; 2006 [cited 2024 Sep 17]. p. 58–64. Available from: https://link.springer.com/chapter/10.1007/978-3-540-33101-8_8
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539–61.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008 Oct;59(4):596–601.
Jemec GBE, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 1):191–4.
Jemec GBE. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119(3):345–50.
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013 Mar;68(3):412–9.
Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97–103.
Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol. 2014 Oct 1;28(7):1013–27.
Pink AE, Simpson MA, Desai N, Dafou D, Hills A, Mortimer P, et al. Mutations in the ?-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012;132(10):2459–61.
Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol. 2011 May;164(5):1017–22.
Kathju S, Lasko LA, Stoodley P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol. 2012 Jul;65(2):385–9.
Guet-Revillet H, Coignard-Biehler H, Jais JP, Quesne G, Frapy E, Poirée S, et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014 Dec 1;20(12):1990–8.
Matusiak ?, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601–3.
Van Der Zee HH, De Ruiter L, Van Den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-?, interleukin (IL)-1? and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-? and IL-1?. Br J Dermatol. 2011 Jun;164(6):1292–8.
Hessam S, Sand M, Gambichler T, Bechara FG. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015 Dec 1;73(6):998–1005.
Brown TJ, Rosen T, Orengo IF. Hidradenitis suppurativa. South Med J. 1998;91(12):1107–14.
Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: Pathogenesis and management. Br J Plast Surg. 2003;56(5):451–61.
Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325–8.
Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–4.
Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009 Aug;219(2):148–54.
Mendonça CO, Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006 May;154(5):977–8.
Van Der Zee HH, Boer J, Prens EP, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009 Aug;219(2):143–7.
Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014 Jan;28(1):125–6.
Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016 Dec 1;41(8):852–7.
Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poirée S, Fraitag S, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011 Feb;222(1):49–58.
Megna M, Bettoli V, Chimenti S, Chiricozzi A, Naldi L, Virgili A, et al. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-? agents. G Ital Dermatol Venereol. 2015;150:731–9.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul 1;81(1):91–101.
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May 1;180(5):1009–17.
Theut Riis P, Thorlacius LR, Jemec GB. Investigational drugs in clinical trials for Hidradenitis Suppurativa. Expert Opin Investig Drugs. 2018 Jan 2;27(1):43–53.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMC. 2021;372:n71.
Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GBE. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011 Aug;165(2):391–8.
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012 Dec 18;157(12):846–55.
Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–94.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4;375(5):422–34.
Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016;22(3):13030.
Giamarellos-Bourboulis EJ, Sobell J, Ryan C, Wolkenstein PJ, Geng Z, Mulder GD. Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies. Wounds. 2017;29(11):E98–102.
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019 Jan 1;80(1):60-69.e2.
Kimball AB, Sundaram M, Shields AL, Hudgens S, Okun M, Foley C, et al. Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. J Am Acad Dermatol. 2018 Dec 1;79(6):1141–3.
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial. Ann Intern Med. 2012 Dec 18;157(12):846–55.
Kim ES, Garnock-Jones KP, Keam SJ. Adalimumab: A Review in Hidradenitis Suppurativa. Am J Clin Dermatol. 2016 Oct 1;17(5):545–52.
Shukla S, Bhargava A, Chatterjee A, Srivastava J, Singh N, Singh SP. Pharmacology of TNF inhibitors. Plant Foods Hum Nutr [Internet]. 2006 Mar [cited 2024 Sep 17];61(1):23–44. Available from: https://link.springer.com/chapter/10.1007/3-7643-7438-1_3
Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT pharmacometrics Syst Pharmacol. 2017 Sep 1;6(9):576–88.
Caccavale S, Tancredi V, Boccellino MP, Babino G, Fulgione E, Argenziano G. Hidradenitis Suppurativa Burdens on Mental Health: A Literature Review of Associated Psychiatric Disorders and Their Pathogenesis. Life. 2023 Jan 1;13(1).
Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, et al. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology. 2016 Apr 1;232(6):687–91.
Muralidharan V, Pathmarajah P, Peterknecht E, Qazi E, Barlow R, Muralidharan V, et al. Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. 2021 Jan 1;34(1).
Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol Res Rev. 2012 May 3;4:33.
Daoud M, Suppa M, Benhadou F, Daxhelet M, Njimi H, White J, et al. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data. Front Med. 2023;10.
DOI: 10.5457/ams.v55i1.825
